ArticleJournal of clinical microbiology2019
Point-Counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute Recommendations for Reporting Antimicrobial Susceptibility Results.
Article in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metronidazole Susceptibility Patterns in EuropeanMedical sciences (Basel, Switzerland) · 2026Pooled it
- Safety Evaluation ofFood science & nutrition · 2026Article
- Five-Year Evolution of the Microbiological Landscape of Diabetic Foot Infections (2021-2025): Rising Polymicrobial Gram-Negative Predominance and Emergence of Resistant Enterobacterales at a Single Large-Volume Outpatient Centre.Antibiotics (Basel, Switzerland) · 2026Article
- Performance evaluation of antimicrobial susceptibility testing methods for ceftazidime-avibactam and imipenem-relebactam against Klebsiella pneumoniae and Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Diagnostics for priority bacterial pathogens: global gaps and research needs for curbing antimicrobial resistance in low-resource settings.The Lancet. Microbe · 2026Review
- Article
- Bacterial diversity and antibiotic susceptibility profile of the isolates from public vehicles in Butwal Sub-Metropolitan City, Rupandehi, Nepal.PLOS global public health · 2026Article
- Prevalence, Appropriateness, and Outcomes of Colistin Use in Multidrug-ResistantMedicina (Kaunas, Lithuania) · 2025Article
- Occurrence ofMicroorganisms · 2025Article
- Microbial mediated silver nanoparticles enhance the potential of bioactive metabolites in the medicinal plantRSC advances · 2025Article
- Antimicrobial Susceptibility ofMicroorganisms · 2025Article
- ClinicalOpen veterinary journal · 2025Article
- Biological characterization of novelFrontiers in microbiology · 2025Article
- Inaccurate communication in health sciences: The case of 'partial artemisinin resistance' for the treatment of malaria.New microbes and new infections · 2024Article
- Antimicrobial Resistance ofAntibiotics (Basel, Switzerland) · 2024Article
- Antibiotic susceptibility testing using minimum inhibitory concentration (MIC) assays.npj antimicrobials and resistance · 2024Article
- Characterization and Comparative Genomic Analysis of vB_BceM_CEP1: A Novel Temperate Bacteriophage Infecting Burkholderia cepacia Complex.Journal of microbiology (Seoul, Korea) · 2024Article
- Trends in the Prevalence of Antimicrobial Resistance in Escherichia coli Isolated from Outpatient Urine Cultures in French Amazonia.The American journal of tropical medicine and hygiene · 2024Article
- Development of Ultrasound-Processed Poppy (ACS omega · 2024Article
- Phenotypic identification of different β-Lactamases in intrinsic and acquired colistin resistant uropathogenic gram negative bacteria.Pakistan journal of medical sciences · 2024Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTIONAntibiotic susceptibility test results are among the most important results issued by clinical microbiology laboratories because they routinely guide critical treatment decisions. Interpretations of MIC or disk diffusion test results, such as "susceptible" or "resistant," are easily understood. Clinical laboratories also need to determine whether and how their reports will reflect more complex situations. Such situations include, first, whether there is need to administer higher or more frequent doses of antibiotic than usual for clinical efficacy; second, whether an antimicrobial is likely to be effective at a body site where it concentrates; and third, whether there is some uncertainty in the test results due to technical variability that cannot be eliminated. Two leading organizations that set standards for antimicrobial susceptibility testing, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI), have taken different strategies to deal with these challenges. In this Point-Counterpoint, Gunnar Kahlmeter and Christian Giske discuss how EUCAST is addressing these issues, and Thomas Kirn and Susan Sharp discuss the CLSI approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.